Abstract
Huntington's disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding the huntingtin protein (Htt), however, the means by which neurodegeneration occurs remains obscure. There is evidence that mutant Htt interacts with transcription factors leading to reduced histone acetylation. We report that administration of the histone deacetylase inhibitor phenylbutyrate after onset of symptoms in a transgenic mouse model of HD significantly extends survival and attenuates both gross brain and neuronal atrophy. Administration of phenylbutyrate increased brain histone acetylation and decreased histone methylation levels as assessed by both immunocytochemistry and Western blots. Phenylbutyrate increased mRNA for components of the ubiquitin-proteosomal pathway and down-regulated caspases implicated in apoptotic cell death, and active caspase 3 immunoreactivity in the striatum. These results show that administration of phenylbutyrate, at doses that are well tolerated in man, exerts significant neuroprotective effects in a transgenic mouse model of HD, and therefore represents a very promising therapeutic approach for HD.
Highlights
Huntington’s disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding the huntingtin protein (Htt), the means by which neurodegeneration occurs remains obscure
Histone acetylation is reduced in cell lines that express a mutant androgen receptor with an expanded polyglutamine repeat, and this is reversed by overexpression of CREB-binding protein (CBP) or by treatment with histone deacetylase (HDAC) inhibitors, with a concomitant reduction in cell loss [11]
We found that the HDAC inhibitor phenylbutyrate exerts significant effects on survival and ameliorates histopathologic degeneration in the N171-82Q transgenic mouse model of HD when administered after the onset of symptoms
Summary
Huntington’s disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding the huntingtin protein (Htt), the means by which neurodegeneration occurs remains obscure. Phenylbutyrate increased mRNA for components of the ubiquitin-proteosomal pathway and down-regulated caspases implicated in apoptotic cell death, and active caspase 3 immunoreactivity in the striatum These results show that administration of phenylbutyrate, at doses that are well tolerated in man, exerts significant neuroprotective effects in a transgenic mouse model of HD, and represents a very promising therapeutic approach for HD. Histone acetylation is reduced in cell lines that express a mutant androgen receptor with an expanded polyglutamine repeat, and this is reversed by overexpression of CBP or by treatment with HDAC inhibitors, with a concomitant reduction in cell loss [11]. We found that the HDAC inhibitor phenylbutyrate exerts significant effects on survival and ameliorates histopathologic degeneration in the N171-82Q transgenic mouse model of HD when administered after the onset of symptoms. We show for the first time that histone methylation is markedly increased in the N171-82Q transgenic mouse model of HD, and that this is ameliorated by phenylbutyrate treatment
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
